Business Description
LENZ Therapeutics Inc
NAICS : 541720
SIC : 2834
ISIN : US52635N1037
Description
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 362.1 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 95.17 | |||||
| 9-Day RSI | 85.24 | |||||
| 14-Day RSI | 76.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.47 | |||||
| Quick Ratio | 11.47 | |||||
| Cash Ratio | 11.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -9.98 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -337.23 | |||||
| ROA % | -31.86 | |||||
| ROIC % | -1809.8 | |||||
| ROC (Joel Greenblatt) % | -8752.2 | |||||
| ROCE % | -37.84 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.9 | |||||
| Price-to-Tangible-Book | 2.9 | |||||
| EV-to-EBIT | -8.31 | |||||
| EV-to-EBITDA | -8.31 | |||||
| EV-to-FCF | -7.21 | |||||
| Price-to-Net-Current-Asset-Value | 2.9 | |||||
| Price-to-Net-Cash | 2.96 | |||||
| Earnings Yield (Greenblatt) % | -12.03 | |||||
| FCF Yield % | -7.82 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LENZ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
LENZ Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -4.458 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 76.54 | ||
| 14-Day ATR ($) | 1.054428 | ||
| 20-Day SMA ($) | 18.3825 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 14.42 - 24.59 | ||
| Shares Outstanding (Mil) | 25.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
LENZ Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
LENZ Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
LENZ Therapeutics Inc Frequently Asked Questions
What is LENZ Therapeutics Inc(LENZ)'s stock price today?
The current price of LENZ is $22.50. The 52 week high of LENZ is $24.59 and 52 week low is $14.42.
When is next earnings date of LENZ Therapeutics Inc(LENZ)?
The next earnings date of LENZ Therapeutics Inc(LENZ) is 2024-08-30 Est..
Does LENZ Therapeutics Inc(LENZ) pay dividends? If so, how much?
LENZ Therapeutics Inc(LENZ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers